BioSpace News Archive

Pneuma Respiratory, a healthcare company focused on the advancement of inhaled respiratory therapeutics, is attending this week’s 41st Annual J.P. Morgan Healthcare Conference in San Francisco to unveil the latest iteration of its fully digital soft mist inhaler.

Calidi Biotherapeutics, Inc. and First Light Acquisition Group announced they have entered into a definitive merger agreement to create a public company focused on developing oncolytic viral therapies with stem cell-based delivery platforms to treat a wide range of cancers with significant unmet needs.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the “Subsidiary” or “PAPL”) for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of cannabinoids (“Sol-Gel License”).

Novotech announced the acquisition of EastHORN, a European CRO with clinical, medical and regulatory expertise in multiple strategically important locations across the continent.

ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.

Biofrontera Inc. (Nasdaq:BFRI) today announced that the first patient has been dosed in a Phase 3 randomized, double-blind, vehicle-controlled, multicenter clinical study to evaluate the safety and efficacy of Ameluz® and BF-RhodoLED® XL in the field-directed treatment of actinic keratosis (AK) on the extremities, neck and trunk.

Bexson Biomedical, Inc. announced the U.S. Patent and Trademark Office has issued patent 11,534,454 titled Complexing Agent Salt Formulations of Pharmaceutical Compounds.

SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, today announced that David Lowndes will be appointed as Chief Operating Officer.

Revive Therapeutics Ltd. announces an independent published study, titled “Omicron Spike Protein Is Vulnerable to Reduction” from the University of Toronto, which evaluated the potential disruption of the SARS-CoV-2 virus spike protein by various FDA-approved mild anti-oxidants has shown that Bucillamine had the most potent effect on COVID-19 Omicron variants when compared to these anti-oxidants being explored as a potential treatment for COVID-19.

Syneos Health®, the only fully integrated biopharmaceutical solutions organization, announced that, effective March 31, 2023, Jason Meggs will transition from his role as Chief Financial Officer to pursue other career opportunities.